UPDATE: Indonesia considers three more CLs

10 December 2007

Three second-line antiretroviral drugs are being considered for compulsory licensing by the Indonesian government, adding to the three front-line treatments already affected by the exploitation of a loophole in the World Trade Organization's Trade-Related aspects of Intellectual Property rights (TRIPs). This allows compulsory licensing in cases where a WTO member considers that a public health interest is served.

Samsuridjal Djauzi, a physician who also lectures at the University of Indonesia in the country's capital, Jakarta, told Intellectual Property Watch that the US developed drugs Gilead's Viread (tenofivir), Bristol-Myers Squibb's Videx (didanosine) and Abbott Laboratories' Kaletra/Aluvia (lopinavir) are being investigated by his team on behalf of the Indonesian Ministry of Health. Dr Djauzi added that about 10,000 HIV/AIDS patients in Indonesia are using first-line ARVs, of which less than 5% would develop resistance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



More ones to watch >






Company Spotlight